Compare GLP-1 Medications: Semaglutide vs Tirzepatide
Choosing the right GLP-1 medication depends on your health profile, weight loss goals, and personal preferences. At Transformation Health, we offer three distinct programs, each built around different active ingredients and dosing strategies, but all including provider-led care, lab work, and ongoing support.
This guide breaks down the differences so you can have an informed conversation with your provider. For a broader overview of GLP-1 treatment, visit our GLP-1 weight loss programs page.
Program Comparison at a Glance
| GLP-1 Semaglutide | GLP-1/GIP Tirzepatide | Microdose GLP-1/GIP | |
|---|---|---|---|
| Monthly Price | $249 (injectable) / $279 (oral) | $339 | $199 |
| Active Ingredient | Semaglutide | Tirzepatide | Tirzepatide + NAD+, B12 |
| Mechanism | GLP-1 receptor agonist | Dual GLP-1/GIP agonist | Low-dose dual agonist + supplements |
| Formulations | Injectable or oral | Injectable | Injectable or oral |
| Min. BMI | 27 (or 25 w/ condition) | 27 (or 25 w/ condition) | 20 |
| Best For | First-time GLP-1 patients | Patients seeking dual-action therapy | Weight maintenance |
| Labs Included | Yes | Yes | Yes |
| Free Shipping | Yes | Yes | Yes |
| Cancel Anytime | Yes | Yes | Yes |
All programs include medication, provider care, lab work, 24/7 support, and free shipping. View full pricing details ->
Not Sure Which Is Right for You?
Take our free 5-minute assessment and a licensed provider will evaluate your health profile to recommend a program, if clinically appropriate.
Get StartedQuick Program Comparison
Microdose GLP-1/GIP
Maintenance & support
$199/mo
Oral or injectable
- Tirzepatide, NAD+, B12
- Maintenance support
- Clinical team access
- BMI 20+ eligible
- Free shipping
GLP-1 (Semaglutide)
Injectable or Oral
$249/mo injectable
$279/mo oral
- Reduces food noise
- Increases fullness
- Personalized coaching
- Provider care & labs included
- Free shipping
GLP-1/GIP (Tirzepatide)
Dual-action metabolic formula
$339/mo
Oral or injectable
- Dual-action GLP-1/GIP
- Comprehensive health coaching
- Provider care & labs included
- Free shipping
- Cancel anytime
All plans include medication, provider care, labs, 24/7 support, and free shipping. No hidden fees.
GLP-1 Semaglutide - $249/mo (Injectable) or $279/mo (Oral)
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has shown significant weight loss benefits in large-scale clinical trials. It works by mimicking the GLP-1 hormone your body naturally produces after eating.
How It Works
Semaglutide targets GLP-1 receptors in your brain and gut to:
- Reduce appetite by signaling your brain’s satiety center
- Slow gastric emptying so you feel full longer after meals
- Regulate blood sugar by enhancing insulin secretion
Clinical Evidence
The STEP 1 trial enrolled 1,961 participants and demonstrated that semaglutide achieved average weight loss of 14.9% of body weight over 68 weeks [1]. Participants also saw improvements in blood pressure, cholesterol, and blood sugar markers. The most common side effects were nausea and diarrhea, which typically improved as the body adjusted to the medication [1].
Importantly, the SELECT trial demonstrated that semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% in people with overweight or obesity [3]. This cardioprotective effect extends benefits beyond the scale.
Compounded formulations have not been independently evaluated by the FDA. The active ingredient semaglutide has been studied extensively in FDA-approved branded products, but compounded versions are prepared by licensed pharmacies and may differ in formulation, purity, and potency.
Who Should Choose Semaglutide?
- You are starting GLP-1 therapy for the first time and want a well-studied medication
- You prefer oral medication, as semaglutide is the only GLP-1 we offer in pill form
- You want a proven, flexible option with extensive clinical data and cardiovascular benefits behind it
- You are seeking long-term metabolic support with evidence of heart health benefits
Your $249/mo (or $279/mo oral) covers: Semaglutide medication, U.S.-licensed provider care, comprehensive lab work, personalized coaching, 24/7 message support, and free shipping. No hidden fees.
GLP-1/GIP Tirzepatide - $339/mo
Tirzepatide is a dual-action medication that targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This two-pronged approach addresses appetite and metabolism from multiple hormonal pathways.
How It Works
By activating both GLP-1 and GIP receptors, Tirzepatide:
- Suppresses appetite through enhanced satiety signaling
- Improves insulin sensitivity via dual-receptor activation
- Increases energy expenditure through broader metabolic effects
Clinical Evidence
The SURMOUNT-1 trial enrolled 2,539 participants and demonstrated that tirzepatide produced weight loss ranging from 16% to 22.5% of body weight, depending on dose, over 72 weeks [2]. This represents substantially more weight loss than semaglutide monotherapy.
More importantly for body composition, tirzepatide produced approximately 3 times more fat loss than lean muscle loss [6]. This distinction matters because lean muscle is metabolically active and helps maintain energy expenditure long-term. The SURMOUNT trials showed this favorable body composition change across all age groups, including perimenopausal women.
Common side effects included nausea and diarrhea early in treatment, which typically improved over time [2]. Compounded formulations have not been independently evaluated by the FDA. The active ingredient tirzepatide has been studied extensively in FDA-approved branded products, but compounded versions are prepared by licensed pharmacies and may differ in formulation, purity, and potency.
Who Should Choose Tirzepatide?
- You are interested in a dual-action approach that targets both GLP-1 and GIP receptors
- You have tried semaglutide and want to explore a different mechanism of action
- You have a higher BMI and your provider recommends dual-receptor therapy
- You are prioritizing preservation of lean muscle mass while losing fat
- You are comfortable with injectable or oral administration
Your $339/mo covers: Tirzepatide medication, comprehensive health coaching, U.S.-licensed provider care, lab work, 24/7 support, and free shipping.
Microdose GLP-1/GIP - $199/mo
Our microdose program combines lower-dose tirzepatide with supportive supplements (NAD+, L-Carnitine, and B12) designed for patients focused on maintenance or those with a lower BMI. This is the only affordable long-term maintenance tier in the market.
How It Works
The microdose approach provides:
- Lower therapeutic doses of GLP-1/GIP agonists for ongoing appetite management without aggressive weight loss
- NAD+ for cellular energy and metabolic function
- L-Carnitine for fat metabolism support
- B12 for energy and neurological health
Who Should Choose Microdose?
- You have already reached your goal weight and want to maintain results long-term
- You have a lower BMI (20+) and want metabolic support rather than aggressive weight loss
- You have prior GLP-1 experience and want to continue at a lower dose
- You want an affordable maintenance option with supplemental metabolic benefits
- You prefer a sustainable, lower-dose approach to ongoing appetite management
Your $199/mo covers: Microdose medication with supplements, clinical team access, lab work, and free shipping.
Ready to Take the Next Step?
Complete our free assessment and a licensed provider will evaluate your health profile to determine which medication may be clinically appropriate.
Get StartedHow to Decide: A Practical Guide
Your provider will ultimately recommend whichever medication is clinically appropriate based on your health evaluation, but here is a practical framework for thinking about your options:
By health goal
Significant weight to lose: Semaglutide or Tirzepatide. Your provider will recommend which is clinically appropriate based on your health profile and goals.
Interested in better fat loss vs. muscle loss: Tirzepatide's 3-to-1 fat-to-lean-mass ratio [6] makes it an option if preserving muscle during weight loss is a priority.
Want cardiovascular benefits: Semaglutide showed a 20% reduction in major cardiovascular events in the SELECT trial [3].
Maintaining current weight: The Microdose program is designed for long-term weight maintenance.
By budget
$199/mo - Microdose (maintenance, BMI 20+)
$249/mo - Semaglutide injectable (first-time patients)
$279/mo - Semaglutide oral (prefer pills over injections)
$339/mo - Tirzepatide (dual-action GLP-1/GIP therapy)
All prices are locked in. Your rate will not increase. See our full pricing page for details.
By preference
Prefer oral medication? Semaglutide oral ($279/mo) is your only non-injectable option.
Want evidence-backed efficacy? Both semaglutide [1] and tirzepatide [2] have extensive clinical trial data from large, independent studies.
Already lost weight? The Microdose program is designed for maintenance without higher-dose therapy.
Switching Between Programs
You’re not locked into one medication. Many patients follow a natural progression:
Start on Semaglutide or Tirzepatide
Begin with a full-dose program during the active weight loss phase. Your provider will recommend the medication that is clinically appropriate for your health profile.
Reach Your Goal Weight
Over 6-12 months, work with your care team toward your target. Your provider monitors your progress through regular check-ins and lab work.
Transition to the Microdose Program
Move to affordable long-term maintenance at $199/mo. Your care team manages the transition seamlessly - no new assessment needed. They'll adjust your dosing gradually to ensure a smooth switch.
Important Information About Compounded Medications
The medications available through Transformation Health are compounded formulations prepared by licensed, US-based compounding pharmacies. The active ingredients (semaglutide and tirzepatide) are also found in certain FDA-approved branded products (Ozempic(R), Wegovy(R), Mounjaro(R), and Zepbound(R)), but compounded versions may differ in formulation, purity, and potency.
As with all compounded medications, these specific formulations are not FDA-approved [7]. The FDA-approval process is designed for mass-produced, branded drugs. Compounded medications are prepared for individual patients and are not subject to the same large-scale review. Your licensed provider will determine the most appropriate treatment based on your individual health profile.
For complete details, visit our medical disclosures page.
Citations
[1] Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/ (STEP 1 trial: 14.9% average weight loss over 68 weeks, 1,961 participants, nausea and diarrhea as most common side effects)
[2] Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/ (SURMOUNT-1 trial: 16-22.5% weight loss over 72 weeks, 2,539 participants, 3 times more fat loss than lean mass loss)
[3] Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/37952131/ (SELECT trial: 20% reduction in major adverse cardiovascular events)
[4] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Prescription Medications to Treat Overweight and Obesity.” https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
[5] U.S. Food and Drug Administration. “FDA Approves New Medication for Chronic Weight Management (Zepbound).” November 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
[6] Neeland IJ, et al. “Changes in lean body mass with GLP-1-based therapies.” Diabetes, Obesity and Metabolism. 2024. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15728 (Evidence of preferential fat loss over lean mass with tirzepatide)
[7] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers